Telmisartan is an angiotensin II receptor antagonist (ARB). It is marketed by Boehringer Ingelheim under the tradename Micardis®. Telmisartan is also marketed by Glaxo Group Ltd under the trademark Pritor®. ARBs are prescribed primarily in the treatment of hypertension.
New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials.